Phase 3 Study Showed MACUGEN® Improved Vision Over Standard of Care in Patients with Diabetic Macular Edema
Patients on MACUGEN Maintained and Expanded Vision Gains Over Two Years
NEW YORK, N.Y., (June 5, 2010) /PRNewswire/ — Results from a Phase 3 study demonstrate MACUGEN® (pegaptanib sodium) significantly improved vision in patients with diabetic macular edema (DME), a complication of diabetes that is a leading cause of blindness in people of working age.¹ In the study, 37 percent of patients treated with MACUGEN gained two lines, or 10 letters, of vision on the ETDRS eye chart at 54 weeks, compared to 20 percent of patients who received a sham (placebo-like) procedure which consists of anesthesia and a simulated injection in the eye (p=0.0047). The data were presented today at the World Ophthalmology Congress in Berlin by Frank G. Holz, an investigator in the trial and director of the University Eye Hospital at the University of Bonn in Germany.
“These encouraging Phase 3 results demonstrate that MACUGEN has the potential to improve vision in people with DME, a serious complication of chronic diabetes,” said Marla B. Sultan, M.D., M.B.A., global clinical lead for MACUGEN at Pfizer. ”Currently there are no approved pharmaceutical treatments for DME, and when left untreated, about one out of four people with this condition will develop moderate vision loss within three years,” said Dr. Sultan. “Pfizer is pleased to be exploring MACUGEN as a potential treatment option to address this unmet medical need.”